November 2018 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016, and the 2017/18 Invitation to Tender, dated 2 November 2017.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
---|---|---|---|---|---|---|
Potassium Iodate |
Tab 253 mcg (150 mcg elemental iodine); |
$4.69 |
$4.69 |
NeuroTabs |
1 January 2019 |
1 April 2019 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
---|---|---|---|---|---|---|---|
Potassium Iodate |
Tab 253 mcg (150 mcg elemental iodine); |
$4.69 |
$4.69 |
NeuroTabs |
1% |
1 January 2019 |
1 March 2019 |
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date |
Brand (Supplier) affected by reference pricing and delisting |
---|---|---|---|---|---|---|---|---|
Baclofen |
Inj 2 mg per ml, 5 ml ampoule; |
$209.29 per 1 ampoule |
$372.98 |
Medsurge |
1 February 2019 |
1 April 2019 |
1 July 2019 |
Lioresal Intrathecal |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
4. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
---|---|---|---|---|---|---|---|
Irinotecan hydrochloride1 |
Inj 20 mg per ml, 5 ml vial, 1 vial pack |
$17.80 |
$71.44 |
Irinotecan Actavis 100 |
1% |
1 February 2019 |
1 April 2019 |
1 The price and subsidy of irinotecan hydrochloride inj 20 mg per ml, 5 ml vial in Section B of the Pharmaceutical Schedule will also be amended from 1 February 2019. The subsidy for irinotecan hydrochloride inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Schedule will change from $0.19 per 1 mg to $0.75 per 1 mg from 1 April 2019. |
5. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
---|---|---|---|---|---|---|---|---|
Baclofen |
Inj 2 mg per ml, 5 ml ampoule; |
$209.29 per 1 ampoule |
$372.98 |
Medsurge |
1% |
1 February 2019 |
1 April 2019 |
Lioresal Intrathecal |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2017/18 Invitation to Tender, dated 2 November 2017
2017/18 Invitation to Tender
Chemical name |
Line item |
---|---|
Baclofen |
Inj 0.05 mg per ml, 1 ml ampoule |
Irinotecan |
Inj 20 mg per ml, 2ml ampoule |
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.